The decision by London boroughs to provide more than 4,000 extra places on the NHS-led PrEP Impact Trial is a major boost to HIV prevention in the capital.

There is extensive evidence that HIV transmissions are reduced when PrEP – an HIV prevention medicine – is used by people at high risk of exposure. This is why promoting PrEP is an integral part of the boroughs' collaborative London HIV Prevention Programme, which has overseen sizeable reductions in new HIV diagnoses in recent years.